Sign in
NGM Stock Price, Chart, Stats & News
NGM Biopharmaceuticals, Inc.
Save
128.53M
Market cap
–
Current P/E
–
Forward P/E
NGM chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 49.72% |
Operating margin | -3317.79% |
Pretax margin | -3223.34% |
Net margin | -3223.34% |
Effective tax rate | – |
ROA | -84.31% |
ROE | -69.76% |
D/E | – |
Interest coverage ratio | – |
NGM valuation
P/E | – |
P/S | 29.10x |
P/B | 0.85x |
P/CF | -0.96x |
P/FCF | -0.96x |
P/OCF | -0.96x |
PEG | -0.01x |
EV multiple | -1.30x |
About
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH.
Similar securities
Based on sector and market capitalization
Report issue